We are pleased to share with you our latest research report, which delves into the current landscape of the Indian equity markets and provides valuable insights into identifying alpha-generating opportunities. In this comprehensive study, we explore key market trends, sector performance, and our Scientific Investing Framework designed to help investors navigate the market with greater…
Read more
Defence manufacturing in India continues to break new records year after year, with the country’s total defence output reaching INR 1.27 lakh crores in FY2024, growing by approximately 17% from FY2023, and nearly 60% since FY2020, representing an annualized growth rate of approximately 12.6%. With INR 6.2 lakh crores in military spending, India is currently…
Read more
As the United States transitions to a new administration under former President Donald Trump, investors are evaluating potential shifts in U.S. economic and geopolitical strategies. Dr. Vikas Gupta, CEO and Chief Investment Strategist of OmniScience Capital, provides insights into how these changes could impact markets and offers guidance on positioning portfolios to benefit from new…
Read more
With nearly four million electric vehicles (EVs) sold in India cumulatively by March this year, the market is in the midst of an explosive growth phase and will become a major power consumer. With an anticipated total power consumption of approximately 100 TWh by 2030, EVs have the potential to rank among the nation’s single…
Read more
“Electric Vehicles will dominate Indian roads by 2030 as the government targets 30% EV penetration on Indian roads by 2030. There are numerous government programs and subsidies, such FAME and PLI in place to encourage the use of EVs in India. “With an anticipated total power consumption of approximately 100 TWh by 2030, EVs have…
Read more
“The Fed’s rate cuts are likely to stimulate growth, with U.S. equities and emerging markets expected to gain in the long term, despite near-term volatility. For global investors, especially in emerging markets like India, cheaper financing could boost investment flows, particularly from Foreign Institutional Investors (FIIs).” – Dr. Vikas Gupta, CEO & Chief Investment Strategist…
Read more
There is excitement in the pharma space, but with the Nifty Pharma index’s price-to-earnings (PE) valuation multiple at 38, the sector is fully priced for its growth outlook. Based on our scientific investing framework, we recommend taking some profits rather than increasing exposure.” -Ashwini Shami (EVP and Portfolio Manager – OmniScience Capital) with Moneycontrol …
Read more
The investment universe needs to be broadened to non-conventional proxy defence and other forms of more subtle defence so that undervalued companies can be found.” – Vikas Gupta CEO, OmniScience Capital Read More
The fundamentals of defence stocks remain extremely strong in terms of revenue, profits, growth visibility, and order books. A few pure play defence stocks are still investible from a valuation perspective, but many appear overvalued. – Dr Vikas Gupta Read More
India’s GDP growth for the quarter ending June 2024 registered at 6.7%, slightly below expectations. While this indicates a modest slowdown, the underlying data remains encouraging, with strong growth in private consumption and a notable rise in investment activity.” Read Dr. Vikas Gupta’s views on India’s Q1 GDP numbers. Read More
Recent Comments